Standard Historical Balance Sheet
LAB Stock | USD 1.94 0.08 3.96% |
Trend analysis of Standard Biotools balance sheet accounts such as Total Current Liabilities of 114.8 M provides information on Standard Biotools' total assets, liabilities, and equity, which is the actual value of Standard Biotools to its prevalent stockholders. By breaking down trends over time using Standard Biotools balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Standard Biotools latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Standard Biotools is a good buy for the upcoming year.
Standard Biotools Inventory |
|
Standard |
About Standard Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Standard Biotools at a specified time, usually calculated after every quarter, six months, or one year. Standard Biotools Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Standard Biotools and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Standard currently owns. An asset can also be divided into two categories, current and non-current.
Standard Biotools Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Standard Biotools assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Standard Biotools books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Standard Biotools balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Standard Biotools are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Standard Biotools' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.At present, Standard Biotools' Short and Long Term Debt Total is projected to decrease significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 114.8 M, whereas Total Assets are forecasted to decline to about 228.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 111.6M | 102.7M | 98.2M | 104.4M | Total Assets | 275.2M | 390.3M | 323.1M | 228.8M |
Standard Biotools balance sheet Correlations
Click cells to compare fundamentals
Standard Biotools Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Standard Biotools balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 264.8M | 324.8M | 275.2M | 390.3M | 323.1M | 228.8M | |
Short Long Term Debt Total | 60.0M | 95.4M | 111.6M | 102.7M | 98.2M | 104.4M | |
Other Current Liab | 12.7M | 25.6M | 12.2M | 10.5M | 19.3M | 12.6M | |
Total Current Liabilities | 32.8M | 54.2M | 49.6M | 43.4M | 109.3M | 114.8M | |
Total Stockholder Equity | 153.6M | 139.1M | 94.6M | (81.5M) | 163.2M | 171.4M | |
Property Plant And Equipment Net | 12.9M | 55.6M | 65.2M | 59.5M | 54.9M | 57.6M | |
Current Deferred Revenue | 11.8M | 13.5M | 15.5M | 14.4M | 11.6M | 7.8M | |
Net Debt | 38.3M | 26.9M | 83.2M | 21.3M | 46.5M | 49.6M | |
Retained Earnings | (623.6M) | (676.8M) | (736.0M) | (926.1M) | (1.0B) | (950.7M) | |
Accounts Payable | 6.5M | 9.2M | 10.6M | 7.9M | 9.2M | 5.5M | |
Cash | 21.7M | 68.5M | 28.5M | 81.3M | 51.7M | 43.2M | |
Non Current Assets Total | 168.7M | 207.1M | 203.1M | 181.5M | 164.9M | 124.5M | |
Non Currrent Assets Other | 5.5M | 4.7M | 3.7M | 3.1M | 2.3M | 4.4M | |
Cash And Short Term Investments | 58.6M | 68.5M | 28.5M | 165.8M | 114.9M | 72.5M | |
Net Receivables | 19.0M | 25.4M | 18.3M | 17.3M | 19.7M | 15.4M | |
Common Stock Shares Outstanding | 66.8M | 72.0M | 75.8M | 78.3M | 79.2M | 83.1M | |
Short Term Investments | 5.1M | 0.0 | 37.0M | 84.5M | 63.2M | 35.1M | |
Liabilities And Stockholders Equity | 264.8M | 324.8M | 275.2M | 390.3M | 323.1M | 228.8M | |
Non Current Liabilities Total | 78.4M | 131.5M | 131.1M | 428.3M | 50.5M | 48.0M | |
Inventory | 13.9M | 19.7M | 20.8M | 21.5M | 20.5M | 13.6M | |
Other Current Assets | 4.6M | 4.0M | 4.5M | 4.3M | 3.1M | 2.8M | |
Other Stockholder Equity | 777.8M | 815.6M | 831.4M | 846.4M | 854.8M | 467.6M | |
Total Liab | 111.2M | 185.7M | 180.6M | 471.8M | 159.9M | 205.2M | |
Total Current Assets | 96.1M | 117.7M | 72.1M | 208.8M | 158.2M | 104.3M | |
Accumulated Other Comprehensive Income | (582K) | 112K | (907K) | (1.9M) | (2.2M) | (2.1M) | |
Short Term Debt | 1.8M | 5.9M | 9.9M | 9.4M | 68.2M | 71.6M | |
Common Stock | 70K | 75K | 77K | 80K | 83K | 87.2K | |
Intangible Assets | 46.2M | 40.2M | 27.9M | 12.6M | 1.4M | 1.3M | |
Other Assets | 2.6M | 2.7M | 2.4M | 3.1M | 2.8M | 3.4M | |
Long Term Debt | 53.8M | 54.2M | 64.2M | 62.8M | 4.0M | 3.8M | |
Long Term Debt Total | 53.8M | 54.2M | 64.2M | 62.8M | 56.5M | 91.1M | |
Capital Surpluse | 777.8M | 815.6M | 831.4M | 847.0M | 974.1M | 774.5M | |
Cash And Equivalents | 5.0M | 20.7M | 28.5M | 81.3M | 93.5M | 98.2M | |
Property Plant Equipment | 12.9M | 55.6M | 65.2M | 59.5M | 68.5M | 36.3M | |
Other Liab | 20.2M | 39.1M | 29.3M | 20.2M | 23.2M | 28.7M | |
Net Tangible Assets | 372K | (9.7M) | (41.0M) | 110.9M | 127.6M | 134.0M | |
Net Invested Capital | 207.4M | 193.3M | 165.6M | (16.6M) | (84.5M) | (80.3M) | |
Capital Stock | 70K | 75K | 77K | (81.5M) | 83K | 87.2K | |
Non Current Liabilities Other | 573K | 1.3M | 882K | 961K | 1.1M | 888.5K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.